AzTrials
AzTrials

Hyaluronic AcidNCT05579522

Clinical Evaluation of Interdental Papilla Reconstruction Using Injectable Autogenous Fat Versus Hyaluronic Acid Filler.

A study testing Fat graft injection and Hyaluronic acid injection in people with Hyaluronic Acid and Fat Graft, run by Cairo University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this randomized controlled trial is to evaluate the amount of interdental papilla fill following the injection of the fat graft compared to hyaluronic acid filler in patients with interdental papilla deficiency. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Hyaluronic Acid, Fat Graft
What is being tested?
Fat graft injection and Hyaluronic acid injection
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
No sites listed yet
Study dates
10 Oct 2022to 1 Apr 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Highly motivated patients having at least one deficient papilla in the inter-bicuspid region.
  • Papillary deficiency types I or II, according to Nordland and Tarnow classification [13]
  • No radiographic evidence of bone loss interproximally. (Cardaropoli et al,2004)
  • Full mouth plaque index (PI) and gingival index (GI) scores should be less than 20%.
  • No open contacts between affected teeth should be present.
  • Teeth free from caries, proximal restorations, fixed prosthesis or orthodontic appliances

Who cannot join

  • Subjects with medical conditions that may affect periodontal healing or regeneration.
  • Subjects with a history of allergic reactions, smokers, and alcoholics
  • Pregnant or breastfeeding females
  • Patients with current or previous drugs intake that may predispose to gingival enlargement.
  • Patients under orthodontic treatment or had orthodontic treatment in the past six months
  • Patients with a history of periodontal surgeries over the last six months at the area of interest

About this study

Official title: Clinical Evaluation of Interdental Papilla Reconstruction Using Injectable Autogenous Fat Compared To Hyaluronic Acid In Patients With Interdental Papillary Deficiency: A Randomized Controlled Clinical Trial.

The goal of this randomized controlled trial is to evaluate the amount of interdental papilla fill following the injection of the fat graft compared to hyaluronic acid filler in patients with interdental papilla deficiency. Highly motivated patients having at least one deficient papilla with the presence of a contact point between adjacent teeth in the inter-bicuspid region. Papillary deficiency types I or II, according to Nordland and Tarnow (1998)classification will be selected. The main question it aims to answer is: In patient with interdental papillary deficiency, will injecting autogenous fat increase papilla height compared to hyaluronic acid injection? Participants in the test group will receive fat graft injection in the inter dental papilla. In the injection phase, 3 injections will be given at each papilla site: at baseline, 3 and 6 weeks intervals. While in the control group, hyaluronic acid injection in the interdental papilla and also 3 injections will be given at each papilla site at the same intervals.

Read the detailed description

The treatment protocol will be divided into 3 phases: the pre-operative phase, where patients will be examined for eligibility, the treatment phase, where both control and interventional treatments will be carried out and finally the follow up phase, where patients will be followed up for the duration of the study.

A- Preoperative Evaluation A.1. Medical History A thorough detailed personal and dental history will be collected from all patients. Medical evaluation will be done before enrolling patients in the study to exclude the presence of any disease that may contraindicate treatment or exclude the patient from the study.

A.2. Clinical evaluation Initial periodontal therapy including full mouth supragingival scaling and subgingival debridement and patient motivation and education for proper oral hygiene.

After 6 weeks, re-evaluation of the deficient papilla will be done, and the degree of papillary deficiency according to Nordland and Tarnow classification [13] will be determined. Plaque and gingival indices will also be assessed and used to determine eligibility. Only patients with deficient papilla fulfilling the inclusion criteria will be recalled discussing all treatment options and sign the informed consent.

Once enrolled in the study, alginate impression will be taken for the involved arch/arches to construct study casts and fabricate customized stents to standardize measurements throughout the study. Standardized digital clinical photographs will also be taken for the GBT as a baseline measurement of the dimension of the black triangle. One-week later patients will be scheduled for the 1st injection.

A.3. Radiographic evaluation The distance between the contact area and inter-proximal bone crest (CP-BC) will then be measured to determine eligibility at the sites of papillary deficiency using peri-apical radiographs with paralleling technique and then confirmed by bone sounding.

B- Treatment phase:

In the injection phase, 3 injections will be given at each papilla site: at baseline, 3 and 6 weeks intervals.

  1. Clinical measurement of the height of the black triangle will be by measuring the distance between the deficient papilla tip and contact area (PT-CP distance) to the nearest 0.5 mm (baseline). This will be done using a graduated periodontal probe and the fabricated customized stent for proper and standardized positioning of the probe at each measurement interval.
  2. Standardized digital clinical photographs will be taken for the eligible deficient papillae for the baseline measurement of the surface area of black triangles.
  3. Local anesthesia will be administered by infiltration to achieve the necessary anesthesia to allow a comfortable treatment procedure.
  4. Patient allocation concealment will be broken to determine will treatment:

The patient will be randomly assigned to one of the treatment groups:

  • Group A (Test): Fat graft injection in the inter dental papilla.
  • Group B (Control): Hyaluronic acid injection in the interdental papilla.

Control group (Hyaluronic acid injection in the interdental papilla):

  • The deficient papilla will be injected with 0.1 mm of HA gel concentration of 20 mg/ml using a 30-gauge disposable insulin syringe.
  • The needle will be inserted 2-3 mm apical to the tip of the interdental papilla and directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically.
  • The papilla will be lightly molded in an incisal direction for 1 minute using gauze.

Test group (Fat graft injection in the inter dental papilla):

  • Free buccal fat graft will be harvested from the buccal pad of fat.
  • After administering anesthesia in the posterior area at the depth of the vestibule, a small horizontal incision in the free mucosa above the second and the third maxillary molars will be created using a sharp #11 blade.
  • Through blunt dissection, the fat tissue will be accessed and easily mobilized into the oral cavity by progressive blunt dissection.
  • The desired amount of fat will be harvested, and the remaining buccal pad will be pushed back in its place.
  • Interrupted sutures with 5-0 vicryl resorbable sutures will be used to achieve primary closure of the incision.
  • The fat graft will be rinsed to remove any debris and mechanically emulsified.

Fat emulsification

  • Emulsification of the fat will be done by shifting the fat between two 10-cc syringes connected to each other by a female-to-female Luer-Lok connector processing the block fat graft into nano-fat (Tonnard et al., 2013).
  • After 30 passes, the fatty liquid will be filtered over a sterile nylon cloth and the fluid will be collected in a sterile syringe. This is done to remove any connective tissue remnants that could block the fine needles.
  • A 30-gauge disposable insulin syringe will be used to load the nano-fat graft and will be inserted 2-3 mm apical to the tip of the interdental papilla.

Postoperative phase:

After completion of the treatment, self-care instruction will be given to the patients

Patient self-care instructions (Heitz-Mayfield 2008):

  • Avoid mechanical plaque control in the area for 24 hours after the injection.
  • Oral hygiene should be maintain using a soft toothbrush after the first 24 hours.
  • Antiseptic mouth rinse, Chlorhexidine mouth rinse will be prescribed twice per day for two weeks.

Follow up and post-operative evaluation Patients will be recalled after 3 and 6 months from the first injection where clinical measurement of the gingival black triangle dimensions and standardized digital clinical photographs will be retaken.

The outcomes are:

  1. Black triangle height
  • The black triangle height (BTH) will be assessed using standardized digital clinical photographs and analyzed by an image analysis program (Photoshop Cs 5, Adobe Systems, San Jose, CA, USA).
  • Method of aggregation: Mean
  • Specific measurement time point: at baseline, after 3 weeks, 6 weeks and 6 months postoperatively.
  1. Black triangle area
  • The surface area of the black triangle (BTA) will be assessed using standardized digital clinical photographs and analyzed by an image analysis program (Photoshop Cs 5, Adobe Systems, San Jose, CA, USA).
  • Method of aggregation: Mean
  • Specific measurement time point: at baseline, after 3 weeks, 6 weeks and 6 months postoperatively.
  1. Black triangle width
  • The black triangle width (BTW) will be assessed using standardized digital clinical photographs and analyzed by an image analysis program (Photoshop Cs 5, Adobe Systems, San Jose, CA, USA).
  • Method of aggregation: Mean
  • Specific measurement time point: at baseline, after 3 weeks, 6 weeks and 6 months postoperatively.
  1. Post-Surgical Patient Satisfaction:
  • A 3-item questionnaire will be asked to the patients and a VAS scale for 0-10 will be used.
  • These items will be: Would you experience the same procedure another time? To what extent are you satisfied about the procedure? To what extent are you satisfied with the results?
  1. Post-operative pain Visual Analogue Scale (VAS) with numbers from 0 to 10 ('no pain' to 'worst pain imaginable') will be measured at 24 hours.

Criteria for Discontinuing or Modifying Intervention:

Intervention will be discontinued or modified if the patient is unable to commit to the follow-up schedule or has any conditions that prevents him/her to continue the study.

Strategies to improve adherence to intervention:

  • Patients will be recalled monthly for supportive periodontal therapy during the course of the study.
  • Close follow up by phone will be done to ensure patient engagement
Being tested
Fat graft injection, Hyaluronic acid injection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fat graft injectionProcedure or surgery

    Fat graft injection in the interdental papilla.

  • Hyaluronic acid injectionProcedure or surgery

    Hyaluronic acid injection in the interdental papilla

Study groups in NCT05579522
Study groupRoleWhat they receive
injectable fat graftExperimentalInjection of fat graft from the buccal pad of fat into the interdental papilla
Receives: Procedure: Fat graft injection
hyaluronic acid fillerActive comparatorinjection of hyaluronic acid filler in the interdental papilla
Receives: Procedure: Hyaluronic acid injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change in Black Triangle Height (BTH)

    • The black triangle height (BTH) will be assessed using standardized digital clinical photographs and analyzed by an image analysis program (Photoshop Cs 5, Adobe Systems, San Jose, CA, USA).

    Measured: Specific measurement time point: at baseline and after 6 months postoperatively.

Secondary outcomes (4)
  1. change in Black triangle area

    • The surface area of the black triangle (BTA) will be assessed using standardized digital clinical photographs and analyzed by an image analysis program (Photoshop Cs 5, Adobe Systems, San Jose, CA, USA).

    Measured: Specific measurement time point: at baseline and after 6 months postoperatively.

  2. change in Black triangle width

    The black triangle width (BTW) will be assessed using standardized digital clinical photographs and analyzed by an image analysis program (Photoshop Cs 5, Adobe Systems, San Jose, CA, USA).

    Measured: Specific measurement time point: at baseline and after 6 months postoperatively.

  3. Post-operative pain

    Visual Analogue Scale (VAS) with numbers from 0 to 10 ('no pain' to 'worst pain imaginable')

    Measured: will be measured at 24 hours.

  4. Post-Surgical Patient Satisfaction:

    A 3-item questionnaire will be asked to the patients and a VAS scale for 0-10 will be used.

    These items will be: Would you experience the same procedure another time? To what extent are you satisfied about the procedure? To what extent are you satisfied with the results?

    Measured: will be measured after 1 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Oct 2022
  2. Study start10 Oct 2022 (estimated)
  3. Primary completion1 Apr 2024 (estimated)
  4. Study completion1 Apr 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05579522
Sponsor's protocol ID
PER313
Status last verified
Oct 2022
First submitted
7 Oct 2022
Last updated
13 Oct 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: the protocol, the results and the conclusion

Questions about this trial

What is this clinical trial studying?

A study testing Fat graft injection and Hyaluronic acid injection in people with Hyaluronic Acid and Fat Graft, run by Cairo University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change in Black Triangle Height (BTH) (time frame: Specific measurement time point: at baseline and after 6 months postoperatively.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in